Product image of Ocrevus (Ocrelizumab) 300mg / 10ml Vials supplied by GNH India

Ocrevus

Active Ingredient:
Ocrelizumab
Form:
Vials
Brand:
Ocrevus
Origin:
Germany

Ocrevus (Ocrelizumab Vials) 300mg / 10ml

Ocrelizumab, the active ingredient in Ocrevus, is a humanized monoclonal antibody presented as a 300mg/10ml vial for intravenous infusion use. It is used to treat relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

GNH India supplies Ocrevus as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Strength

300mg / 10ml

Pack Size

1s

Storage

2-8°

Manufacturer / TM Owner

Roche Diagnostics GmbH

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ocrevus is a disease-modifying therapy used in the treatment of multiple sclerosis (MS).

  • Relapsing forms of multiple sclerosis (RMS): Reduces the frequency of MS relapses and slows the progression of disability.
  • Primary progressive multiple sclerosis (PPMS): Slows the progression of disability and reduces the rate of brain volume loss.

How It Works

  • Ocrelizumab works by binding to CD20-positive B cells, which are a type of immune cell involved in the inflammatory process of multiple sclerosis. This binding leads to the depletion of these B cells, thereby modulating the immune response and reducing inflammation in the central nervous system.

Side Effects

Ocrevus can cause various side effects, ranging from common to serious or rare.

Common Side Effects

  • Infusion-related reactions such as fever, chills, and fatigue.
  • Upper respiratory tract infections.
  • Skin infections.
  • Herpes infections.
  • Back pain.
  • Joint pain.
  • Skin rashes.
  • Hair thinning.

Serious or Rare Side Effects

  • Serious infections, including opportunistic infections.
  • Progressive multifocal leukoencephalopathy (PML), a rare brain infection.
  • Hepatitis B reactivation.
  • Hypersensitivity reactions.
  • Liver problems.
  • Heart problems, including heart attack and stroke.

Precautions & Warnings

Ocrevus should be used with caution and under the supervision of a healthcare professional. Important precautions include:

  • Infections: Ocrevus can increase the risk of infections. Patients should be monitored for signs of infection.
  • Vaccinations: Live or live-attenuated vaccines should not be given during or before treatment with Ocrevus.
  • Hepatitis B: Patients should be tested for hepatitis B before starting treatment.
  • Progressive multifocal leukoencephalopathy (PML): Patients should be monitored for signs of PML.
  • Hypersensitivity reactions: Patients should be monitored for signs of allergic reactions.
  • Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ocrevus may interact with other medications, which can affect its efficacy or increase the risk of side effects.

Major Interactions (Avoid)

  • Live or live-attenuated vaccines: Should not be given during or before treatment with Ocrevus.
  • Immunosuppressants: May increase the risk of infections when used with Ocrevus.
  • Biologic therapies: May increase the risk of infections when used with Ocrevus.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: May increase the risk of infections when used with Ocrevus.
  • Immunomodulators: May increase the risk of infections when used with Ocrevus.
  • Other medications that affect the immune system: Should be used with caution when combined with Ocrevus.

Frequently Asked Questions

Ocrevus is used to treat relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). It helps to reduce the frequency of MS relapses, slow the progression of disability, and reduce the rate of brain volume loss.

Ocrelizumab works by binding to CD20-positive B cells, which are a type of immune cell involved in the inflammatory process of multiple sclerosis. This binding leads to the depletion of these B cells, thereby modulating the immune response and reducing inflammation in the central nervous system.

The dosage of Ocrevus is determined by a healthcare professional based on the patient's condition and response to treatment. The initial dose is typically 300 mg, followed by 600 mg two weeks later, and then 600 mg every six months.

The safety of Ocrevus during pregnancy or breastfeeding has not been established. Pregnant women or those planning to become pregnant should discuss the risks and benefits with their healthcare provider. It is not known whether Ocrelizumab passes into breast milk.

To order Ocrevus from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will reply with pricing, availability, shipping, and the import paperwork.

Ocrevus is a disease-modifying therapy specifically designed to target B cells involved in the inflammatory process of MS. It is different from other MS treatments that target different immune cells or pathways. The choice of treatment depends on the individual patient's condition and response to therapy.

Ocrevus should be stored at 2-8°C, refrigerated, protected from light, and not frozen or shaken. It should be handled with care and administered by a healthcare professional trained in intravenous infusion.

Ocrevus is administered as an intravenous infusion by a healthcare professional. The initial dose is typically 300 mg, followed by 600 mg two weeks later, and then 600 mg every six months. The infusion process usually takes a few hours.

The most serious risks associated with Ocrevus include serious infections, progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation, hypersensitivity reactions, and heart problems. Patients should be monitored closely for these risks.

Ocrevus should not be used by individuals with a known hypersensitivity to Ocrelizumab or any of its components. It should also be used with caution in patients with active infections, hepatitis B, or a history of heart problems. Patients should consult their healthcare provider to determine if Ocrevus is suitable for them.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ocrelizumab

Ocrevus 300mg/10ml

Ocrevus 300mg/10ml

300mg / 10ml Vials
Ocrevus

Ocrevus

300mg / 10ml Vials
Ocrevus

Ocrevus

300mg / 10ml Vials
Ocrevus 30 mg

Ocrevus 30 mg

30 MG SOLUTION

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT